Back to results
US 10,307,509 B2Granted
Hemostatic foam
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsAndreas Goessl, Katarzyna Gorna
Life of this patent
Estimating the term…
Abstract
The invention discloses a pharmaceutical hemostatic liquid foam base preparation comprising albumin as foaming agent and a fibrinogen precipitating substance and optionally a coagulation inducing agent, wherein albumin as foaming agent is present in native form; a method for the production of a transient hemostatic liquid foam; the transient hemostatic liquid foam; and a kit for making the foam.
Claims20
A combination product comprising:
- a pharmaceutical hemostatic liquid foam base preparation, wherein the pharmaceutical liquid foam base preparation comprises albumin as foaming agent and a fibrinogen precipitating substance, wherein the albumin as foaming agent is present in native form, and
- a foaming gas, wherein:
- the pharmaceutical hemostatic liquid foam base preparation is a solution and
- the concentration of the albumin in the pharmaceutical hemostatic liquid foam base preparation is from 5% to 40% w/v.
1 more element
A pharmaceutical hemostatic liquid foam obtainable by a method comprising:
- providing a pharmaceutical hemostatic liquid foam base preparation comprising albumin and thrombin, wherein:
- albumin is present in its native form,
- albumin is not crosslinked, and
- thrombin is present in a concentration of 100 to 10000 IU/ml;
- and
- contacting the pharmaceutical hemostatic liquid foam base preparation with a foaming gas so as to obtain the pharmaceutical hemostatic liquid foam, wherein:
- the pharmaceutical hemostatic liquid foam base preparation is a solution,
- the pharmaceutical hemostatic liquid foam degrades in less than or equal to about 5 times the time necessary to achieve hemostasis, and
- the concentration of the albumin in the pharmaceutical hemostatic liquid foam base preparation is from 5% to 40% w/v.
6 more elements
A kit for producing a pharmaceutical hemostatic liquid foam, comprising
- (a) a first container comprising a pharmaceutical hemostatic liquid foam base preparation, wherein the pharmaceutical hemostatic liquid foam base preparation comprises:
- albumin in its native form, and
- a fibrinogen precipitating substance, and
- (b) a second container containing a foaming gas, wherein:
- the pharmaceutical hemostatic liquid foam base preparation is a solution and
- the concentration of the albumin in the pharmaceutical hemostatic liquid foam base preparation is from 5% to 40% w/v.
3 more elements
Dependencies are inferred from the claim text.